Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A quick guide helps you compare 401(k) options for your 30s, focusing on fees, employer matches, and potential tax outcomes.
24,750 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
Freddie Mac data show mortgage rates climbed to their highest level in almost four months, pushing the 30-year loan t...
Markets in 2026 push households to reexamine Ramsey’s disciplined framework. This article examines Dave Ramsey’s 5-St...
Bitcoin dipped over the weekend, but traders rotated into infrastructure-focused bets as the Bitcoin Hyper presale su...
An insurer’s blockbuster profit alongside an insider stock sale creates a compelling investing puzzle. This article b...
A quiet crisis is forming in the real estate lending world. This article explains the $3 trillion challenge, who feel...
Analysts issued fresh price targets on nine stocks, signaling divergent views as U.S. markets contend with rate uncer...
Chevron's CEO warns that jet fuel shortages may push aviation costs higher as carriers trim schedules and consumers f...
NVIDIA's Huang warns of a potential AI leadership shift as Huawei accelerates its chip ambitions. Markets react as in...
Coinbase missed earnings and then endured a multi-hour outage tied to an AWS failure, shaking investors. bulls argue ...
As the 10-year yield hovers near 4.4%, many investors chase top-yield REITs for income. The real cost chasing reit be...